



Changing cancer care together

# 3

## All.Can at three years: annual report

The All.Can initiative is made possible with financial support from Bristol Myers Squibb (main sponsor), Roche (major sponsor), Amgen, MSD and Johnson & Johnson (sponsors), and Baxter (contributor), with additional non-financial (in kind) support from Helpsy, Intacare and Goings-On.

# Contents

Section  
01

Foreword

Section  
02

Our members

Section  
03

Launch of the patient survey findings

Section  
04

All.Can around the world

Section  
05

The All.Can efficiency hub

# Foreword

**The past year has been very exciting for All.Can, with the launch of the All.Can patient survey findings and continued expansion of our membership base. All.Can International has transitioned to become an independent non-profit organisation, based in Brussels. It is headed by a new CEO, Eduardo Pisani. This is an important step in our growth and will open up opportunities for us to continue to drive our mission to provide pragmatic solutions to sustainable cancer care.**

All.Can's presence around the world has also grown, with four new national initiatives joining the All.Can family in 2019. All.Can is now established in 15 countries, involving nearly 300 stakeholders across the world – and more countries are already in the process of developing national initiatives.

With All.Can now three years old, we wish to celebrate the many developments and achievements that have been happening in different countries through the All.Can national initiatives.

Building on the foundations of the international patient survey, many of the national initiatives developed their own lessons from the findings, focusing on topics of highest relevance to the national context. There is much to learn from their work, and this report aims to facilitate the exchange of information and inspire other countries to join the All.Can family.

Following on the heels of our previous annual reports, this document is testament to how All.Can is continuing to evolve as a movement and international network, bringing together widespread efforts to achieve our vision of a world where patients are always at the heart of sustainable cancer care.



# Our members

All.Can international is made up of 26 members representing a broad scope of sectors and a vast range of knowledge and expertise.



All.Can International is currently funded by six private companies: Bristol Myers Squibb (main sponsor), Roche (major sponsor), Amgen, MSD and Johnson & Johnson (sponsors), and Baxter (contributor). We also have three knowledge partners, which contribute in kind (non-financial) support to All.Can: Helpsy, Intacare and Goings-On.

We continue to engage with a variety of healthcare organisations, including private-sector companies, to join All.Can International. As All.Can International transitions into an independent non-profit organisation in 2020, we feel it is important that our membership reflects the broad spectrum of actors involved in cancer care. Our next phase of research in 2020 will focus on the role of data in cancer care, so we are particularly interested in engaging further partners in the data and information technology space.

# 2019: an overview

## Launch of the All.Can patient survey findings

**All.Can's third year saw the launch of the All.Can patient survey findings.** Throughout 2018, the All.Can patient survey collected responses from current and former cancer patients and caregivers in more than 10 countries to gather their perspectives on where they had encountered inefficiency in their care, and help identify where efforts were most needed to improve the efficiency of cancer care.

Nearly 4,000 cancer patients and caregivers across the world responded to the survey to share their experiences. Based on both quantitative and qualitative findings, four key opportunities for improvement were identified.

### Four key opportunities for improvement identified in the patient survey:

- Ensure swift, accurate and appropriately delivered diagnosis
- Improve information-sharing, support and shared decision-making
- Make integrated multidisciplinary care a reality for all patients
- Address the financial impact of cancer

All.Can

Responses to the patient survey report demonstrated the extent to which the findings resonated with their own personal experiences of cancer.

**'I [participated in the All.Can patient survey] because the questions it posed resonated with concerns I've had during my 15 year journey. [The survey findings] provide valuable insight into where care is not meeting patients' needs.'**

Tessa Richards,  
Senior Editor, The BMJ



# Sharing the findings

Findings of the survey were featured in several notable publications.

Find full details of media coverage of the survey findings on the [All.Can website](#).

Findings were also presented at several notable conferences:

- European CanCer Organisation (ECCO) Summit: opening session
- European Society of Medical Oncology (ESMO) – European Oncology Nursing Society (EONS) Nursing Track: featured in the European Cancer Patient Coalition (ECPC) presentation
- International Brain Tumour Alliance (IBTA) Brain Tumour Summit opening session

## La Repubblica

### Un malato oncologico su tre non ha un aiuto psicologico

*Il 70% dei pazienti vorrebbe un supporto ma spesso il servizio non è "disponibile". Lo rivela un sondaggio condotto su circa 4000 malati di cancro in 10 paesi da All.Can international cancer initiative*

di TINA SIMONELLI

24 luglio 2019

UN malato di cancro su tre non ha accesso a un supporto psicologico, anche se pensa di averne bisogno. È risultato dall'ultimo rapporto All.Can International cancer initiative, realizzato sulla base dei risultati di un sondaggio che ha coinvolto circa 4000 pazienti affetti da diversi tipi di tumore in 10 paesi, tra cui l'Italia.

**7 su 10 avrebbero bisogno dello**

## Cancerworld

### Nearly half of cancer patients don't feel involved in treatment decisions, survey finds

CARLOTTA JARACH

29 July 2019 News 0

Almost half (47%) of patients with cancer do not think that they have been sufficiently involved in the treatment decision process. This is what the international All.Can cancer initiative reveals in its report *Patient insights on cancer care: opportunities for improving efficiency*, along with other patients' outlooks concerning support and adequate information and care beyond the disease.

The All.Can patient survey was conducted internationally, with adapted versions in 10 countries, and aims to obtain patients' perspectives on where they felt they faced inadequacy in their care, looking at the entire care continuum as well as the broader impact of cancer on their lives.

"Patients are often forgotten when it comes to cancer care planning," said Alex Filicevas, Head of EU Affairs at the European Cancer Patient Coalition and member of All.Can international's steering committee. "With the prevalence, complexity and costs of cancer rising across the globe, it is imperative to listen to what patients say would improve their experience of care. Ignoring the findings of this report would be a missed opportunity to do the right thing by patients and make changes that could make a real difference."

## The BMJ

### Nearly half of cancer patients don't feel involved in treatment decisions, survey finds

BMJ 2019;366:doi:https://doi.org/10.1136/bmj48777 (Published 25 July 2019)  
Cite this as: BMJ 2019;366:48777

Article Related content Metrics Responses

Elisabeth Mahase

Author affiliations

Almost half (47%) of patients with cancer do not think that they have been sufficiently involved in deciding which treatment option is best for them, a new survey shows.

The survey of nearly 4000 patients across 10 countries also found that around four in 10 (39%) said that they were never or only sometimes given enough support to deal with symptoms and side effects.

which works to improve ...

## Medscape

News > Medscape Medical News > Oncology News

### Cancer Patients Report Lack of Info and Support

Liam Davenport  
August 02, 2019

Read Comment

An international survey of patients with cancer has highlighted inefficiencies in diagnosis, as well as lack of information and psychological support. Only half of the patients surveyed felt that they were sufficiently involved in decision making.

The survey was conducted in almost 4000 patients and their caregivers from 10 countries, including Australia, Belgium, Canada, the United Kingdom, and

## All.Can around the world

### Three new national initiatives

2019 saw the addition of three new national initiatives to the All.Can family.



**All.Can Norway** will publicly launch in 2020 following several round-table discussions in 2019. Project planning is underway to develop recommendations for improvements in Norwegian cancer care.



**All.Can Austria** is set to launch several projects in 2020, including a patient survey. It is also planning to lead a health congress.



**All.Can Argentina** is planning to conduct a national patient survey during 2020, to determine the areas of inefficiency in cancer care. All.Can Argentina also conducted an exploratory study on diagnosis with expert stakeholder interviews.

## Building on the patient survey at the national level

Following the publication of the All.Can patient survey report, several national initiatives undertook an array of activities throughout 2019 to disseminate survey findings. Many also built on these findings to develop specific activities or projects suited to their national context.

The remainder of this report presents an overview of how the All.Can patient survey findings have been disseminated in different countries and the activities that selected national All.Can initiatives undertook in 2019.

**Note:** The national initiatives in Denmark and Sweden are not featured in this report, as they both spent 2019 working on internal reorganisation and are planning activities for 2020. In addition, neither France nor the United States is featured in this report; while the patient survey was conducted in both these countries, they do not currently have All.Can national initiatives.







## All.Can Australia

The patient survey in Australia was conducted in partnership with All.Can Australia and the University of Western Australia.

What were the most reported areas of inefficiency in cancer care?

- **23%** initial cancer diagnosis
- **19%** dealing with ongoing side effects
- **15%** dealing with the psychological impact

‘One of the things that stood out for me in the patient survey was the regional differences in the care that people receive across Australia. One of the problems with our health system is that we look at episodes of care, rather than looking across the cancer journey. I’d really like to see this work continue and to build on it so we can have a fuller picture around cancer care. This is just the start.’

Alison Verhoeven,  
All.Can Australia steering committee



Click the image below to watch the All.Can Australia video based on the patient survey findings.



## 2019 at a glance

All.Can Australia received notable media coverage for the national-level survey findings, including radio interviews and national print coverage. [Click here to download the press release.](#)

The initiative produced a video based on the survey findings, which outlined the common inefficiencies impacting patient outcomes.

A [value-based healthcare-related seminar](#) in Perth, Western Australia, featured discussions of the international and Australian survey findings, including those specific to Western Australia.

The findings were also discussed with the Advisory Group tasked with developing the [Western Australia Cancer Plan 2020–2025](#). This led to many of the findings being used to inform the recommendations in the Plan – for example, boosting clinical trial participation, access to psychosocial support, and navigating cancer care. The plan was published in February 2020.



# What's next?

All.Can Australia will be exploring one key project in 2020 that focuses on **navigating the health system**.

## This project will:

1. Define the optimal role of a Cancer Care Navigator including the skills and range of qualifications required as well explore the tangible benefits and measurable gains for patients;
2. Conduct a feasibility assessment of the relative costs of Cancer Care Navigation to the Australian health system;
3. Model the delivery of Cancer Care Navigators including stakeholder consultation and economic analysis to demonstrate the value; and
4. Present the model and analysis such that it is an effective tool and reference for government communication and public advocacy initiatives.

There are also plans to conduct the survey again in Western Australia for all cancer patients. Planning is ongoing with the WA Cancer & Palliative Care Clinical Implementation Unit, encompassing nearly 10,000 patients.

[See more at all-can.org/national-initiatives/australia/](https://all-can.org/national-initiatives/australia/)



**'Understanding our health system from the perspective of not only the providers of care but the patients is vital if we are to achieve the very best outcomes in cancer diagnosis, treatment and supportive care – and effectively reduce the cancer burden on our society.'**

Christobel Saunders  
Member, All.Can Australia





## All.Can Belgium

The survey in Belgium was conducted in partnership with All.Can Belgium.

What were the most reported areas of inefficiency in cancer care?

- **28%** dealing with ongoing side effects
- **17%** initial cancer diagnosis
- **15%** getting the right treatment

**'The survey provided us with interesting insights from patients. They will guide us in our future projects; achieving sustainable, efficient, innovative and patient-centred care remains our focus.'**

Pia Cox,  
Board member and co-chair of All.Can Belgium





## 2019 at a glance

In March 2019, All.Can Belgium officially launched at an event at the Solvay library in Brussels. Its [memorandum](#) and [vision document](#) contain key messages on patient centricity and innovative, sustainable cancer policies. These documents lay the foundation for the solutions-focused projects that All.Can Belgium is developing with key stakeholders in cancer care.

The initiative produced an [infographic](#) based on the key findings from Belgian survey respondents. It also collaborated with a pilot project called [Allezi](#), supported by the Foundation Against Cancer and The Majin Foundation. Allezi focuses on enabling people to return to work after cancer, as well as training employers to understand their needs.

The project aims to develop a network of certified coaches that can operate independently, providing people and organisations with the necessary information on reintegration to work during and after cancer.

[See more at all-can.org/national-initiatives/belgium/](https://all-can.org/national-initiatives/belgium/)





## All.Can Canada

The survey in Canada was conducted in partnership with All.Can Canada, led by Save Your Skin Foundation.

What were the most reported areas of inefficiency in cancer care?


- **25%** initial cancer diagnosis
- **17%** dealing with ongoing side effects
- **15%** dealing with the psychological impact of cancer

**'Patients are almost never included in conversations about cancer care. We need to listen to what patients say would improve their experience of care. Ignoring the findings of this report would be a missed opportunity to do the right thing by patients and make changes that could make a real difference.'**

Kathy Barnard,  
stage IV melanoma survivor;  
Founder, Save Your Skin Foundation



Click the image below to read the All.Can Canada report of the patient survey findings.



## 2019 at a glance


All.Can Canada released a country-level report of the patient survey findings, which included further analysis of the data from respondents in the four largest Canadian provinces.

The report was widely disseminated among Canadian health media, the patient community, fellow patient groups, healthcare professionals and industry.

Findings from the patient survey were also used to draft a report on the inefficiency and waste in Canadian cancer care, leading discussions at the inaugural All.Can Canada round table in November 2019.



All.Can Canada's multi-stakeholder round table included strong representation from patient groups



## What's next?

A new report, **Consolidated Report of Waste and Inefficiency in Canadian Cancer Care: Multi-Stakeholder Insights and Recommendations**, will be published in 2020. All.Can Canada plans to present this report at several conferences in 2020:

- Canadian Association of Population Therapeutics (CAPT) 2020 Annual Conference
- Canadian Association of Nurses in Oncology (CANO) Annual Conference 2020
- National Health Leadership Conference
- Canadian Centre for Applied Research in Cancer Control (ARCC) Conference 2020
- CADTH 2020 Symposium

Following the round table in November 2019, All.Can Canada will also lead on analysis across the country to assess to what extent patients are receiving an accurate and timely diagnosis of their cancer. These findings will be available in early 2021.

[See more at all-can.org/national-initiatives/canada/](https://all-can.org/national-initiatives/canada/)

**'With a year-long process of gathering data and achieving consensus with stakeholders complete, we are now ready to work towards specific contributions All.Can Canada can make to improve the cancer journey for Canadian patients.'**

Kathy Barnard,  
Stage IV melanoma survivor;  
Founder, Save Your Skin Foundation





# All.Can Germany

The patient survey did not take place in Germany in 2019, but there are plans underway to conduct a survey in 2020.

## 2019 at a glance

2019 has been a year of progress for All.Can Germany. A regional pilot project on cancer care in rural areas is being developed, which will launch in 2020.

In December 2019 a report on cancer aftercare in Germany was developed and an expert round table discussion will be held in 2020.

## What's next?

Alongside the regional pilot, All.Can Germany will be conducting a survey on cancer care in 2020 to establish an evidence base for a pilot project. The German survey aims to gather data using focus groups and in-depth interviews with healthcare professionals, patient representatives and other stakeholders, and will serve as the foundation to conceptualise the regional pilot project. The project will initially focus on cancer care in rural areas, particularly in regard to aftercare and discharge management. Based on this regional pilot, the lessons learnt will be showcased at an event. The goal is to expand the pilot to other regions in Germany.

In 2020, All.Can Germany will organise an expert round table on cancer aftercare. A position paper will be drafted based on the discussion and findings from the round table. A parliamentary event will take place at the German Bundestag towards the end of the year.

All.Can Germany is expanding its steering committee to include a broad range of stakeholders and give the initiative a holistic perspective of the cancer care pathway.

[See more at all-can.org/national-initiatives/germany/](https://all-can.org/national-initiatives/germany/)



**'In 2020 we want to make a noticeable difference for cancer patients in Germany. With a holistic approach and the involvement of a multidisciplinary team of experts, our activities will strongly interlink practice and policy.'**

Dr. Rainer Hess,  
member of All.Can



# All.Can Greece

All.Can Greece conducted a national patient survey in 2019, following on from the international patient survey.

## 2019 at a glance

All.Can's policy report, 'Towards sustainable care: Reducing inefficiencies, improving outcomes' has been [translated](#) into Greek, and over 300 copies have been distributed.

Following on from the international patient survey, All.Can Greece conducted a national patient survey. Results were presented at the initiative's launch event in April 2019. Results were subsequently present in All.Can Greece sessions at congresses and events in Greece.

A [steering committee](#) of 14 members has been formed.

All.Can sessions took place in three key national oncology and health policy congress and presentations in three cities.

## What's next?

All.Can Greece is planning a second national survey in 2020 to determine barriers leading to delays from the time of diagnosis to the start of treatment.



**'At All.Can Greece, efficiency in cancer care is our first priority, using what is important to patients as a compass for all our activities. Working together with all stakeholders in cancer care, we map the serious variations of cancer care in Greece to identify what needs to be improved, by reducing waste and inefficiency. We are determined to inspire a new culture of efficiency and improve the cancer pathway across Greece a step at a time.'**

Kathi Apostolidis,  
All.Can Greece





## All.Can Italy

The survey in Italy was conducted in partnership with All.Can Italy.

What were the most reported areas of inefficiency in cancer care?


- **25%** dealing with the psychological impact of cancer
- **24%** initial cancer diagnosis
- **11%** dealing with ongoing side effects
- **11%** access to patient support groups

‘Evidence from our work in 2019 taught us that a heterogeneous implementation of the existing legislation weakens efficiency targets. Our goal for 2020 is to effectively engage regional institutions and partner with them to identify virtuous organisational models.’

Emilia De Biasi,  
spokesperson for All.Can Italy



Click the image below to read the All.Can Italy report on regional disparities in cancer.



## 2019 at a glance

All.Can Italy has produced a report on regional disparities in cancer. The report includes interviews with regional cancer networks and patient associations as well as analysis of a set of indicators regarding cancer care at various levels, including patient mobility, offer of home care therapies and access to innovation.

Authored by IQVIA Italy, a member of All.Can Italy, the report identifies gaps and inefficiencies in cancer care at a regional level, according to key performance indicators defined by patient associations.

The report finds a general gap in performance between northern and central regions compared to those in the south relating to the efficacy of cancer networks as an organisational model.

The report was launched in late 2019, welcomed by two members of the Health Committee of the Italian Senate, Paola Boldrini and Paola Binetti.



All.Can Italy also organised a seminar on best practice among regional cancer networks in July 2019. The event, which took place in Rome, brought together patients, key opinion leaders and policymakers to discuss the role of cancer networks in improving care. Speakers included representatives of three regional cancer networks: Oscar Bertetto, Director of the Piemonte and Valle d'Aosta network; Sandro Pignata, Scientific Coordinator of the Campania network; and Giovanni Gorgoni, Head of Puglia's Healthcare Agency and Strategic Coordinator of the Puglia network.

The seminar focused on best-practice examples of positive impacts on patient outcomes, which include clear access to diagnosis, multidisciplinary approaches to care and follow-up, and an evidence-based selection of clinical centres for appropriate therapies. These practices have now been recognised as part of the founding principles that should be adopted by all cancer networks in all Italian regions.





Four areas of analysis were included:

- Access to innovation
- Offer concentration
- Integration between territory and hospital
- Interregional mobility

The poster ranks each region according to the score registered for the four areas of analysis.


## What's next?

Based on the findings of its report on regional disparities, All.Can Italy will develop a consensus paper to collect examples of best practice in the organisation of cancer care in terms of value-based resource allocation.

These examples will be collected through active work involving hospital and care units, with a specific focus on areas that can make a difference to patients, such as access to cancer networks, and the organisation of follow-ups and palliative care. Specific focus will also be given to haematology.

See more at [all-can.org/national-initiatives/italy](http://all-can.org/national-initiatives/italy)

Click the image below to download the All.Can Italy poster from the ISPOR conference



# All.Can Poland

The survey in Poland was conducted in partnership with All.Can Poland.


What were the most reported areas of inefficiency in cancer care?

- **27%** dealing with ongoing side effects
- **18%** dealing with the psychological impact of cancer
- **14%** initial cancer diagnosis

## 2019 at a glance

All.Can Poland released a [report on national-level findings](#) from the patient survey, which was covered in national media. All.Can Poland also released a report on diagnosis in oncology, made through 2017-2019. Members of the steering committee presented at several conferences, including:

- Cancer Prevention Conference
- Health Market Forum
- Healthcare Challenges Congress
- Summer Academy for Journalists
- Polish Society of Surgical Oncology (PTCHO) Congress
- Polish Society of Clinical Oncology Congress







## What's next?

In 2020, All.Can Poland will be one of the partners involved in framing a discussion on the work required to improve the quality and sustainability of cancer care in Poland.

The initiative is also developing future projects on the timely diagnosis of cancer. The Ministry of Health aims to improve the timeliness and quality of care and is rolling out breast and lung cancer units across Poland. All.Can Poland will support this project by collaborating with the decision-makers responsible for its implementation throughout 2020, including clinicians, healthcare system specialists and others.

A member of the All.Can Poland Steering Committee is one of the authors of the National Oncology Strategy 2020–2030, which will be introduced later this year.

[See more at all-can.org/national-initiatives/poland/](https://all-can.org/national-initiatives/poland/)

**'In 2020, we plan to continue discussions among representatives of media, patient organisations, oncologists and decision-makers, directed to work out solutions to improve the quality and efficiency of oncological care.'**

Szymon Chrostowski,  
member of All.Can Poland steering committee







## All.Can Spain

While the patient survey was conducted in Spain, there were too few responses to enable national-level analysis. All.Can Spain's work in 2019 has therefore focused on other areas.

### 2019 at a glance

All.Can Spain hosted two working group sessions in 2019, which addressed the two main inefficiencies of cancer care previously identified in Spain:

- A lack of follow-up for long-term survivors
- Limited communication between doctors and patients

The first working group aimed to define actions that would be important from the patient perspective and feasible to implement in Spain in the short term. A total of 10 actions were defined, including the following:

- **Raise awareness of the needs of long-term survivors, collaborating with patient associations**
- **Define a protocol that defines survivorship as a separate part of a patient's cancer journey**
- **Promote the role of a patient navigator nurse as a reference point for long-term survivors**

The second working group aimed to define and discuss the main areas of improvement that currently exist in doctor–patient communication. Proposed actions were discussed in key areas:

- **The need to educate patients about the disease and its symptoms to improve their communication during medical visits**
- **The need to create materials to help patients understand the explanations given by healthcare professionals**
- **The need for an increased use of information technologies to facilitate doctor–patient communication**





An open platform called **All.Can: Changing Cancer in Spain** has been set up to implement the national initiative. The platform is led by the European Patients' Academy on Therapeutic Innovation (EUPATI) and is supported by organisations including cancer patient associations, scientific associations, foundations and pharmaceutical companies.

## What's next?

All.Can Spain will disseminate a set of recommendations at various regional levels in 2020, based on the areas of improvement that were identified throughout 2019.

The initiative will also produce and disseminate local reports based on the two 2019 working group sessions addressing the main inefficiencies in cancer care in Spain.

[See more at all-can.org/national-initiatives/spain/](https://all-can.org/national-initiatives/spain/)



# All.Can Switzerland

The patient survey did not take place in Switzerland.

## 2019 at a glance

In 2019, All.Can Switzerland publicly launched as a non-profit organisation, becoming the first All.Can national initiative to achieve this status.

It organised a dedicated workshop on integrated care for cancer survivors, in collaboration with the Forum for Managed Care and the National Cancer Strategy. Results of this workshop are due to be published in 2020.

**'It was amazing to see the official launch among a diverse group of stakeholders. The credit goes to All.Can Switzerland's vision and passion to make Swiss cancer care better and more efficient. I look forward to hearing more about the continued learnings and results that come from the work being done by All.Can Switzerland.'**

Michelle Calope,  
BMS Switzerland





## 2019 at a glance

All.Can Switzerland has begun conducting a needs-assessment study to analyse the needs of patients and healthcare professionals. The study is being carried out by the University of Geneva, with results to be presented in 2020. The international All.Can patient survey will be used to compare and complement the results of this study. The study's findings will aim to improve public awareness of Swiss cancer care and the potential for efficiencies.

A follow-up workshop with the Forum of Managed Care on value-based healthcare is planned for late 2020.

All.Can Switzerland also plans to launch a project called **Nurse-led clinic in an outpatient oncology network**, with the following ambitions:

- Increase patient satisfaction and improve quality of life for patients and their relatives
- Achieve cost savings
- Improve the efficiency of care processes
- Raise the quality of treatment or care based on predefined quality indicators

[See more at all-can.org/national-initiatives/switzerland](https://all-can.org/national-initiatives/switzerland)

# United Kingdom

The survey in the United Kingdom was conducted in partnership with All.Can UK in 2018. This was the pilot survey, launched before the commencement of the international patient survey.

What were the most reported areas of inefficiency in cancer care?

- **36%** initial cancer diagnosis
- **19%** dealing with ongoing side effects
- **15%** dealing with the psychological impact of cancer

**'A quick and accurate diagnosis is essential if patients are to receive treatment that gives them the best chance of surviving cancer. Only by working together to identify examples of waste and inefficiency in cancer care can we increase efficiency, improve outcomes and save lives.'**

Rachel Power  
Chief Executive, UK Patients Association





## 2019 at a glance

The year began with a flurry of activities for All.Can UK, after the initiative presented the findings of the UK pilot patient survey at the Britain Against Cancer conference, held at the UK parliament in December 2018. Organised by the All-Party Parliamentary Group on Cancer, the conference had over 350 attendees. Its main theme was to celebrate the progress of cancer care in the UK, while aiming to tackle the challenges of the future.

All.Can UK also conducted a series of interviews with patient groups and clinicians in 2019, to further corroborate the findings of the patient survey. Based on these interviews, the initiative is writing a report on psychological support and care, to be published in 2020.

## What's next?

All.Can UK is forming a network of MPs to develop a campaign offering support for fellow parliamentarians affected by cancer.

Alongside the forthcoming report on psychological support and care, this campaign will highlight the importance of support and wellbeing for people affected by cancer. The campaign will be launched at a training event in Parliament in late 2020.

[See more at all-can.org/national-initiatives/uk](https://all-can.org/national-initiatives/uk)

## The All.Can efficiency hub

The All.Can [efficiency hub](#) collects examples of best practice in improving efficiency in cancer care. The aim is to make these best-practice examples readily accessible to all interested parties, and to encourage others to replicate them. The All.Can efficiency hub is, to our knowledge, the first of its kind.

The hub showcases examples – big or small – that have a positive impact on the efficiency of cancer care. It gathers examples from across the entire cancer pathway, from prevention and screening to treatment and follow-up, all the way to end-of-life care and survivorship – and for all cancer types.

## Our work with iPAAC

All.Can is a collaborating partner in the Innovative Partnership for Action Against Cancer (iPAAC), contributing to Work Package 8, addressing the 'Challenges in Cancer Care'.

iPAAC is a European Commission-funded Joint Action that connects nearly 44 partners across Europe to improve cancer control. It aims to implement innovative approaches to cancer control, as well as building on the deliverables of the previous [CANCON Joint Action](#). The project is running from 2018–2020, with the final output being a Roadmap on Implementation and Sustainability of Cancer Control Actions, which will support member states to implement the recommendations.

[For more information, please visit https://www.ipaac.eu](https://www.ipaac.eu)



# What next for All.Can?

In 2020, All.Can International has transitioned to an independent non-profit organisation, with a base in Brussels. It is headed by a new CEO, Eduardo Pisani.

Our research work continues with a new project looking at the role of data in improving efficiency in cancer care. This work builds on the findings of the All.Can patient survey, as it will initially focus on the four key areas of inefficiency identified by patients and caregivers in the survey.

We also expect the All.Can family to continue growing – with burgeoning initiatives and multi-stakeholder discussions already taking place in many countries around the world, and exciting developments in the important work being led by existing national initiatives.

We look forward to forming new partnerships in 2020 and continuing to work together to improve efficiency in cancer care by focusing on what matters to patients.

**Join us. Work with us. Together, we All.Can.**

[www.all-can.org](http://www.all-can.org)

Twitter: [@AllCanGroup](https://twitter.com/AllCanGroup)

Facebook: [@AllCanGroup](https://www.facebook.com/AllCanGroup)

LinkedIn: [All.Can](https://www.linkedin.com/company/all-can)

[secretariat@all-can.org](mailto:secretariat@all-can.org)

The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Roche (major sponsor), Amgen, MSD and Johnson & Johnson (sponsors), and Baxter (contributor), with additional non-financial (in kind) support from Helpsy, Intacare and Goings-On.



Changing cancer care together